Intervention Review

Haloperidol versus placebo for schizophrenia

  1. Claire B Irving1,*,
  2. Clive E Adams2,
  3. Stephen Lawrie3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 12 MAY 2010

Assessed as up-to-date: 22 AUG 2006

DOI: 10.1002/14651858.CD003082.pub2

Database Title

Additional Information

How to Cite

Irving CB, Adams CE, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003082. DOI: 10.1002/14651858.CD003082.pub2.

Author Information

  1. 1

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  2. 2

    University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    University of Edinburgh, Department of Psychiatry, Edinburgh, Scotland, UK

*Claire B Irving, Cochrane Schizophrenia Group, The University of Nottingham, Institute of Mental Health, Sir Colin Campbell Building, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK. Claire.Irving@nottingham.ac.uk. claireirving@btinternet.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 12 MAY 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (61K)Standard (453K)Full (574K)

  1. Current Version

    Haloperidol versus placebo for schizophrenia

    Claire B Irving, Clive E Adams and Stephen Lawrie

    Article first published online: 12 MAY 2010 | DOI: 10.1002/14651858.CD003082.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Haloperidol versus placebo for schizophrenia

    CB Joy, CE Adams and SM Lawrie

    Article first published online: 19 JUL 2006 | DOI: 10.1002/14651858.CD003082

View Full Article (HTML) Summary (61K)Standard (453K)Full (574K)